The Resource Peptide therapeutics : strategy and tactics for chemistry, manufacturing, and controls, editor: Ved Srivastava
Peptide therapeutics : strategy and tactics for chemistry, manufacturing, and controls, editor: Ved Srivastava
Resource Information
The item Peptide therapeutics : strategy and tactics for chemistry, manufacturing, and controls, editor: Ved Srivastava represents a specific, individual, material embodiment of a distinct intellectual or artistic creation found in Sydney Jones Library, University of Liverpool.This item is available to borrow from 1 library branch.
Resource Information
The item Peptide therapeutics : strategy and tactics for chemistry, manufacturing, and controls, editor: Ved Srivastava represents a specific, individual, material embodiment of a distinct intellectual or artistic creation found in Sydney Jones Library, University of Liverpool.
This item is available to borrow from 1 library branch.
- Summary
- Peptide Therapeutics is an essential reference work for students and researchers, in both academia and industry, with an interest in learning about Chemistry Manufacture and Control (CMC), and facilitating the development and manufacture of peptide-based drugs
- Language
- eng
- Extent
- 1 online resource (544 pages).
- Note
- Includes index
- Contents
-
- Cover; Preface; Editor Biography; Contents; Chapter 1 Regulatory Considerations for Peptide Therapeutics; 1.1 Introduction; 1.2 Peptide Quality Assessment at the FDA; 1.3 Overview of the Current Drug Approval Process Employed for Peptide Applications; 1.3.1 The New Drug Application Assessment Process; 1.3.2 Abbreviated New Drug Application Assessment Process; 1.3.3 Post-approval Activities and Life-cycle Management; Disclaimer; Acknowledgements; References; Chapter 2 Regulatory Perspective on Synthetic Peptides in Europe; 2.1 Introduction; 2.2 European Regulatory Network
- 2.3 Guidelines on the Quality of Human Medicines2.4 Overall Control Strategy; 2.5 Documentation in Dossier of Marketing Authorization; 2.6 European Pharmacopoeia (Ph. Eur.); 2.7 Technical Guide for the Elaboration of Monographson Synthetic Peptides and Recombinant DNA Proteins; 2.8 Information to be Provided in Module 3 for Synthetic Peptides (New Active Substances); 2.9 Considerations for Peptides Conjugates; 2.10 Medicinal Product Considerations; 2.11 Synthetic Peptide Vaccines
- 2.12 Synthetic Peptide Development Programmes Using a Biological Medicinal Product as a European Reference Medicinal Product2.13 Requirements for Clinical Trial Applications; 2.14 Scientific Advice and European Initiatives for Early Access Approaches; 2.15 Conclusion; Disclaimer; References; Chapter 3 Biological and Immunogenicity Evaluation Strategy for Therapeutic Peptides: Chemistry, Manufacturing and Controls Perspective; 3.1 Introduction; 3.2 Biological Evaluation; 3.2.1 Strategy for Assay Development; 3.2.2 Considerations for Potency Assay Design and Validation
- 3.3 Assay Development and Validation3.3.1 Ex Vivo Bioassays; 3.3.2 In Vitro Bioassays; 3.3.3 Assay Readouts; 3.3.4 Assay Design; 3.3.5 Cell Line Selection; 3.3.6 Factors Influencing the Assays; 3.3.7 Standards and Controls; 3.3.8 Design of Experiments and Data Analysis; 3.3.9 Assay Validation; 3.4 Specific Assays of Peptide-based Vaccines; 3.4.1 HLA Binding Assays; 3.5 Immunogenicity Evaluation; 3.5.1 Antibody Testing Strategy; 3.5.2 Risk-based Antibody Testing; 3.5.3 Binding Antibody Testing; 3.5.4 Sandwich Immunoassay; 3.5.5 Mass-related Immunoassay; 3.5.6 SPR; 3.5.7 Mass Spectrometry
- 3.5.8 Cytometry-based Immunoassays3.5.9 Acid Dissociation-based Assay for Drug Interference; 3.5.10 Considerations for Binding Antibody Immunoassays; 3.6 Neutralizing Anti-drug Antibody Testing; 3.6.1 Cell-based Neutralizing Antibody Assay; 3.6.2 Cell Line Selection; 3.6.3 Assay Endpoints for Cell-based Assays; 3.6.4 Cell-based Assay Formats; 3.6.5 Considerations for Ligand-binding Antibody Bioassays; 3.7 Specific Assays for Peptide-based Vaccines; 3.7.1 Enzyme-linked Immunospot (ELISpot) Assay; 3.7.2 Surface and Intracellular Staining; 3.8 Conclusion; References
- Isbn
- 9781788016445
- Label
- Peptide therapeutics : strategy and tactics for chemistry, manufacturing, and controls
- Title
- Peptide therapeutics
- Title remainder
- strategy and tactics for chemistry, manufacturing, and controls
- Statement of responsibility
- editor: Ved Srivastava
- Language
- eng
- Summary
- Peptide Therapeutics is an essential reference work for students and researchers, in both academia and industry, with an interest in learning about Chemistry Manufacture and Control (CMC), and facilitating the development and manufacture of peptide-based drugs
- Cataloging source
- UKRSC
- Dewey number
- 615.19
- Index
- index present
- LC call number
- RS431.P38
- Literary form
- non fiction
- Nature of contents
- dictionaries
- http://library.link/vocab/relatedWorkOrContributorName
- Srivastava, Ved
- http://library.link/vocab/subjectName
-
- Peptide drugs
- Peptide drugs
- Label
- Peptide therapeutics : strategy and tactics for chemistry, manufacturing, and controls, editor: Ved Srivastava
- Note
- Includes index
- Antecedent source
- unknown
- Carrier category
- online resource
- Carrier category code
-
- cr
- Carrier MARC source
- rdacarrier
- Color
- multicolored
- Content category
- text
- Content type code
-
- txt
- Content type MARC source
- rdacontent
- Contents
-
- Cover; Preface; Editor Biography; Contents; Chapter 1 Regulatory Considerations for Peptide Therapeutics; 1.1 Introduction; 1.2 Peptide Quality Assessment at the FDA; 1.3 Overview of the Current Drug Approval Process Employed for Peptide Applications; 1.3.1 The New Drug Application Assessment Process; 1.3.2 Abbreviated New Drug Application Assessment Process; 1.3.3 Post-approval Activities and Life-cycle Management; Disclaimer; Acknowledgements; References; Chapter 2 Regulatory Perspective on Synthetic Peptides in Europe; 2.1 Introduction; 2.2 European Regulatory Network
- 2.3 Guidelines on the Quality of Human Medicines2.4 Overall Control Strategy; 2.5 Documentation in Dossier of Marketing Authorization; 2.6 European Pharmacopoeia (Ph. Eur.); 2.7 Technical Guide for the Elaboration of Monographson Synthetic Peptides and Recombinant DNA Proteins; 2.8 Information to be Provided in Module 3 for Synthetic Peptides (New Active Substances); 2.9 Considerations for Peptides Conjugates; 2.10 Medicinal Product Considerations; 2.11 Synthetic Peptide Vaccines
- 2.12 Synthetic Peptide Development Programmes Using a Biological Medicinal Product as a European Reference Medicinal Product2.13 Requirements for Clinical Trial Applications; 2.14 Scientific Advice and European Initiatives for Early Access Approaches; 2.15 Conclusion; Disclaimer; References; Chapter 3 Biological and Immunogenicity Evaluation Strategy for Therapeutic Peptides: Chemistry, Manufacturing and Controls Perspective; 3.1 Introduction; 3.2 Biological Evaluation; 3.2.1 Strategy for Assay Development; 3.2.2 Considerations for Potency Assay Design and Validation
- 3.3 Assay Development and Validation3.3.1 Ex Vivo Bioassays; 3.3.2 In Vitro Bioassays; 3.3.3 Assay Readouts; 3.3.4 Assay Design; 3.3.5 Cell Line Selection; 3.3.6 Factors Influencing the Assays; 3.3.7 Standards and Controls; 3.3.8 Design of Experiments and Data Analysis; 3.3.9 Assay Validation; 3.4 Specific Assays of Peptide-based Vaccines; 3.4.1 HLA Binding Assays; 3.5 Immunogenicity Evaluation; 3.5.1 Antibody Testing Strategy; 3.5.2 Risk-based Antibody Testing; 3.5.3 Binding Antibody Testing; 3.5.4 Sandwich Immunoassay; 3.5.5 Mass-related Immunoassay; 3.5.6 SPR; 3.5.7 Mass Spectrometry
- 3.5.8 Cytometry-based Immunoassays3.5.9 Acid Dissociation-based Assay for Drug Interference; 3.5.10 Considerations for Binding Antibody Immunoassays; 3.6 Neutralizing Anti-drug Antibody Testing; 3.6.1 Cell-based Neutralizing Antibody Assay; 3.6.2 Cell Line Selection; 3.6.3 Assay Endpoints for Cell-based Assays; 3.6.4 Cell-based Assay Formats; 3.6.5 Considerations for Ligand-binding Antibody Bioassays; 3.7 Specific Assays for Peptide-based Vaccines; 3.7.1 Enzyme-linked Immunospot (ELISpot) Assay; 3.7.2 Surface and Intracellular Staining; 3.8 Conclusion; References
- Control code
- on1114305639
- Dimensions
- unknown
- Extent
- 1 online resource (544 pages).
- File format
- unknown
- Form of item
- online
- Isbn
- 9781788016445
- Media category
- computer
- Media MARC source
- rdamedia
- Media type code
-
- c
- Quality assurance targets
- unknown
- Sound
- unknown sound
- Specific material designation
- remote
- Label
- Peptide therapeutics : strategy and tactics for chemistry, manufacturing, and controls, editor: Ved Srivastava
- Note
- Includes index
- Antecedent source
- unknown
- Carrier category
- online resource
- Carrier category code
-
- cr
- Carrier MARC source
- rdacarrier
- Color
- multicolored
- Content category
- text
- Content type code
-
- txt
- Content type MARC source
- rdacontent
- Contents
-
- Cover; Preface; Editor Biography; Contents; Chapter 1 Regulatory Considerations for Peptide Therapeutics; 1.1 Introduction; 1.2 Peptide Quality Assessment at the FDA; 1.3 Overview of the Current Drug Approval Process Employed for Peptide Applications; 1.3.1 The New Drug Application Assessment Process; 1.3.2 Abbreviated New Drug Application Assessment Process; 1.3.3 Post-approval Activities and Life-cycle Management; Disclaimer; Acknowledgements; References; Chapter 2 Regulatory Perspective on Synthetic Peptides in Europe; 2.1 Introduction; 2.2 European Regulatory Network
- 2.3 Guidelines on the Quality of Human Medicines2.4 Overall Control Strategy; 2.5 Documentation in Dossier of Marketing Authorization; 2.6 European Pharmacopoeia (Ph. Eur.); 2.7 Technical Guide for the Elaboration of Monographson Synthetic Peptides and Recombinant DNA Proteins; 2.8 Information to be Provided in Module 3 for Synthetic Peptides (New Active Substances); 2.9 Considerations for Peptides Conjugates; 2.10 Medicinal Product Considerations; 2.11 Synthetic Peptide Vaccines
- 2.12 Synthetic Peptide Development Programmes Using a Biological Medicinal Product as a European Reference Medicinal Product2.13 Requirements for Clinical Trial Applications; 2.14 Scientific Advice and European Initiatives for Early Access Approaches; 2.15 Conclusion; Disclaimer; References; Chapter 3 Biological and Immunogenicity Evaluation Strategy for Therapeutic Peptides: Chemistry, Manufacturing and Controls Perspective; 3.1 Introduction; 3.2 Biological Evaluation; 3.2.1 Strategy for Assay Development; 3.2.2 Considerations for Potency Assay Design and Validation
- 3.3 Assay Development and Validation3.3.1 Ex Vivo Bioassays; 3.3.2 In Vitro Bioassays; 3.3.3 Assay Readouts; 3.3.4 Assay Design; 3.3.5 Cell Line Selection; 3.3.6 Factors Influencing the Assays; 3.3.7 Standards and Controls; 3.3.8 Design of Experiments and Data Analysis; 3.3.9 Assay Validation; 3.4 Specific Assays of Peptide-based Vaccines; 3.4.1 HLA Binding Assays; 3.5 Immunogenicity Evaluation; 3.5.1 Antibody Testing Strategy; 3.5.2 Risk-based Antibody Testing; 3.5.3 Binding Antibody Testing; 3.5.4 Sandwich Immunoassay; 3.5.5 Mass-related Immunoassay; 3.5.6 SPR; 3.5.7 Mass Spectrometry
- 3.5.8 Cytometry-based Immunoassays3.5.9 Acid Dissociation-based Assay for Drug Interference; 3.5.10 Considerations for Binding Antibody Immunoassays; 3.6 Neutralizing Anti-drug Antibody Testing; 3.6.1 Cell-based Neutralizing Antibody Assay; 3.6.2 Cell Line Selection; 3.6.3 Assay Endpoints for Cell-based Assays; 3.6.4 Cell-based Assay Formats; 3.6.5 Considerations for Ligand-binding Antibody Bioassays; 3.7 Specific Assays for Peptide-based Vaccines; 3.7.1 Enzyme-linked Immunospot (ELISpot) Assay; 3.7.2 Surface and Intracellular Staining; 3.8 Conclusion; References
- Control code
- on1114305639
- Dimensions
- unknown
- Extent
- 1 online resource (544 pages).
- File format
- unknown
- Form of item
- online
- Isbn
- 9781788016445
- Media category
- computer
- Media MARC source
- rdamedia
- Media type code
-
- c
- Quality assurance targets
- unknown
- Sound
- unknown sound
- Specific material designation
- remote
Library Links
Embed
Settings
Select options that apply then copy and paste the RDF/HTML data fragment to include in your application
Embed this data in a secure (HTTPS) page:
Layout options:
Include data citation:
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.liverpool.ac.uk/portal/Peptide-therapeutics--strategy-and-tactics-for/MpVAXOhD61Y/" typeof="Book http://bibfra.me/vocab/lite/Item"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.liverpool.ac.uk/portal/Peptide-therapeutics--strategy-and-tactics-for/MpVAXOhD61Y/">Peptide therapeutics : strategy and tactics for chemistry, manufacturing, and controls, editor: Ved Srivastava</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.liverpool.ac.uk/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.liverpool.ac.uk/">Sydney Jones Library, University of Liverpool</a></span></span></span></span></div>
Note: Adjust the width and height settings defined in the RDF/HTML code fragment to best match your requirements
Preview
Cite Data - Experimental
Data Citation of the Item Peptide therapeutics : strategy and tactics for chemistry, manufacturing, and controls, editor: Ved Srivastava
Copy and paste the following RDF/HTML data fragment to cite this resource
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.liverpool.ac.uk/portal/Peptide-therapeutics--strategy-and-tactics-for/MpVAXOhD61Y/" typeof="Book http://bibfra.me/vocab/lite/Item"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.liverpool.ac.uk/portal/Peptide-therapeutics--strategy-and-tactics-for/MpVAXOhD61Y/">Peptide therapeutics : strategy and tactics for chemistry, manufacturing, and controls, editor: Ved Srivastava</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.liverpool.ac.uk/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.liverpool.ac.uk/">Sydney Jones Library, University of Liverpool</a></span></span></span></span></div>
